The non-profit Institute for Clinical and Economic Review has issued a lukewarm final evidence report on Vertex ...

If you’re looking for trail shoes that are lightweight, flashy, and fun, look no more because the Arc’teryx Vertex Speed ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

Vertex Pharma has said it will use a priority review voucher (PRV) to speed up the FDA review of its new once-daily triple therapy for cystic fibrosis, which has just hit all its objectives in a ...

The non-profit Institute for Clinical and Economic Review has issued a lukewarm final evidence report on Vertex Pharmaceuticals' (NASDAQ:VRTX) non-opioid pain medicine Journavx (suzetrigine).

Analysts' ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The table below summarizes their recent ratings ...